Complex generics are generic versions of pharmaceutical products containing formulations, routes of delivery, dosage forms, drug-device combination products, active ingredients in complex form or features that may make it difficult for products to prove bio-equivalency. NBCD (Non-Biological Complex Drugs) offers workable options for approving complicated generics through optimal utilization of USFDA’s current shortened approval processes, 505(j) and 505(b) (2). The FDA awarded funding on August 2020 to establish the Centre for Research on Complex Generics (CRCG) to address issues related to complex generic development. Complex Generics Face Key Challenges such as bioequivalence standards, substitutability, patent/exclusivity issues, and lifecycle quality assurance. PLGA (poly (lactic-co-glycolic acid)) is a preferred inactive ingredient for long-acting injectable medications with complex formulations. Challenges in creating long-acting injectable/implantable (LAI) drug products are drug loading and release issue, physicochemical properties of PLGA etc. To achieve critical “time-to-market” strategic and operational goals, biopharma businesses should implement Good Regulatory Practices by specifying the where, what, when, and how. Biopharma businesses should select industry partners with clinical experience, worldwide regulatory knowledge, and quality/compliance competence to quickly deliver verified results to avoid problems in the shift to complex generics. The complex generics market is poised for significant growth, increasing from $84 billion in 2024 to $170 billion by 2035, at a compound annual growth rate (CAGR) of 8%. In future the complex generics market will evolve through innovative drug delivery methods, personalized treatment approaches, advanced manufacturing techniques, increased biosimilar products, strategic partnerships to address shifting healthcare needs.
PratibhaAAChalikwarSSBhairavBA. A comprehensive review on complex generics. Bulletin of the Karaganda University “Biology medicine geography Series. 2022; 105(1): 129–135.
3.
Non-Biological Complex Drug Working Group. Non-Biological Complex Drugs Challenges for approval standards and opportunities. 2019. Available at:https://www.fda.gov/media/125176/download(Accessed September 2024).
DeminaNBBakhrushinaEOAnurovaMN, et al.Complex generics as A trend of modern pharmaceutical development. Int J Appl Pharm2024; 16(3): 71–77.
22.
USFDA. Draft GuidanceSameness evaluations in an abbreviated new drug application-active ingredients. 2023. Available at:https://www.fda.gov/media/163018/download(Accessed October 2024).
O'BrienMatthewN. Challenges and opportunities in the development of complex generic long-acting injectable drug products. J Contr Release: Official Journal of the Controlled Release Society2021; 336: 144–158.
26.
GasparRSSilva-LimaBMagroF, et al.Non-biological complex drugs (NBCDs): complex pharmaceuticals in need of individual Robust clinical assessment before any therapeutic equivalence decision. Front Med2020; 7: 590527.
U.S. Food & Drug Administration. Overview of the Regulatory Framework and FDA’s Guidance for the Development and Approval of Biosimilar and Interchangeable Products in the US. 2023. Available at:https://www.fda.gov/media/113820/download(Accessed October 2024).
31.
KleinKBorchardGShahVP, et al.A pragmatic regulatory approach for complex generics through the U.S. FDA 505(j) or 505(b) (2) approval pathways. Ann N Y Acad Sci2021; 1502(1): 5–13.
32.
PatilSKumarSRaoDM, et al.Current regulatory framework and challenges for the approval of complex generics in the US and the EU. Current Indian Science2024; 02: 5.
33.
FreijeILamoucheSTanguayM. Review of drugs approved via the 505(b)(2) pathway: Uncovering drug development trends and regulatory requirements. Ther Innov Regul Sci2020; 54(1): 128–138.
KapoorMLeeSLTynerKM. Liposomal drug product development and quality: current US experience and perspective. AAPS J2017; 19: 632–641.
37.
ICH Reflection Paper. ICH reflection paper further opportunities for harmonization of standards for generic drugs. 2018. Available at:https://www.ich.org/page/reflection-papers2018(Accessed November 2024).
JayachandranP. Advances in quantitative methods and modeling for complex generic drugs and opportunities to hybridize learnings between innovator and generic drug developers. CPT Pharmacometrics Syst Pharmacol2023; 12(5): 549–551.
